ClinicalTrials.gg
Sign In
TerminatedNCT01579864Broncho-SRUpdated Nov 3, 2016

Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia

A Phase 4 interventional study of succinylcholine and rocuronium in Anesthesia, sponsored by Hopital Foch. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Hopital Foch · Phase 4, Interventional, and Treatment

Why this study was terminated
recent publication (Ghezel-Ahmadi. Thorac Cardiovasc Surg. 2014 Nov 21)
Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Myorelaxation is generally used as a part of general anesthesia for interventional rigid bronchoscopy. Succinylcholine is most often used because its short duration of action but rocuronium can be used since sugammadex permits a rapid and complete reversal of the neuromuscular block. The aim of ths study is to compare both agents.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Hopital Foch is the lead sponsor of 215 studies on the registry; 21 are open to participants now.

Browse Hopital Foch studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients scheduled for an interventional rigid bronchoscopy under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • pregnant woman or woman of childbearing age,
  • morbid obesity,
  • drug allergy,contra-indication to succinylcholine, rocuronium, sugammadex, propofol, remifentanil,
  • history of central neurological or brain damage,
  • psychotropic treatment,
  • pacemaker,
  • renal failure,
  • disease of the neuromuscular junction.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
6 participants (actual)

Study arms

  • Active comparator
    succinylcholine

    Succinylcholine 1 mg/kg and a second dose if necessary.

    Drug: succinylcholine

  • Experimental
    Rocuronium

    rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary

    Drug: rocuronium

Interventions

  • Drugsuccinylcholine

    Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue

  • Drugrocuronium

    rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary

06

What researchers measure

Primary outcomes

  1. Score of quality of the surgical procedure

    The quality of the surgical procedure is evaluated by the surgeon (composite score) who is unaware of the neuromuscular agent used (see Fuchs-Buder et al. Acta Anaesthesiol Scand 2007;51(7):789-808)

    Time frame: one day

Secondary outcomes

  1. Score of quality of anesthesia

    The quality of anesthesia is evaluated by the anesthesist in charge on a scale 0-30 (0-10 for the induction ; 0-10 for maintenance; 0-10 for recovery)

    Time frame: one day

07

Study locations

1 site
  • Hopital Foch
    Suresnes, Île-de-France Region 92151, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2012
First posted
Apr 18, 2012
Start
Jan 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01579864
Lead sponsor
Hopital Foch
Responsible party
Sponsor
First posted
Apr 18, 2012
Start date
Jan 2012
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Nov 3, 2016

Study contacts

Morgan Le Guen, MD
principal investigator · Hopital Foch

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocuronium

Other studies from this sponsor

Hopital Foch →

Start the discussion